Who is sponsoring Bêtapain?

Bêtapain is sponsored by University Hospital, Strasbourg, France.

What condition does Bêtapain study?

Bêtapain studies Postthoracotomy Pain, Postthoracoscopy Neuropathic Pain.

What drugs are being tested in Bêtapain?

Interventions: Terbutaline sustained release 5 mg.

What is the status of Bêtapain?

Bêtapain is currently TERMINATED.

Last reviewed 2017-09-07 · How we verify

Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain (Bêtapain)

NCT01582646 Phase 2 TERMINATED

Neuropathic pain is due to a lesion or disease affecting the nervous system. Antidepressants (ADs) are recommended as the first line treatment. In a murine model, the investigators evidenced that antidepressants antiallodynic action is mediated through β2-adrenergic receptor stimulation and that β-mimetics display the same effect. These data support the idea that β-mimetics could offer a therapeutic alternative to ADs for neuropathic pain treatment. This study will aim at assessing the effects of terbutaline on neuropathic pain symptoms.

Details

Lead sponsor	University Hospital, Strasbourg, France
Phase	Phase 2
Status	TERMINATED
Enrolment	20
Start date	2012-01
Completion	2017-09

Conditions

Postthoracotomy Pain
Postthoracoscopy Neuropathic Pain

Interventions

Terbutaline sustained release 5 mg

Primary outcomes

Change from baseline in the average intensity of pain during the last 24 hours reported by the patient on a 11 points Numeric Scale — Day one, day 14 and day 28 of each 4 weeks period

Countries

France